Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]
In development [GID-TAG372] Expected publication date: TBC
Search results
712 results
-
-
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
In development [GID-TAG423] Expected publication date: TBC
-
Pancreatic cancer - capecitabine [ID389]
In development [GID-TAG394] Expected publication date: TBC
-
Melanoma (advanced and metastatic) - temozolomide [ID316]
In development [GID-TAG401] Expected publication date: TBC
-
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
In development [GID-TAG406] Expected publication date: TBC
-
Constipation (opioid induced) - lubiprostone [ID646]
In development [GID-TAG367] Expected publication date: 01 October 2014
-
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]
Proposed [GID-TA10668] Expected publication date: TBC
-
Radiofrequency ablation for palliation of painful spinal metastases
In development [GID-IPG10158] Expected publication date: TBC
-
Magnetic resonance therapy for knee osteoarthritis
In development [GID-IPG10159] Expected publication date: TBC
-
Endobronchial vagal nerve ablation for chronic obstructive pulmonary disease
In development [GID-IPG10160] Expected publication date: TBC
-
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)
In development [GID-IPG10161] Expected publication date: TBC
-
Intramedullary distraction for upper limb lengthening
In development [GID-IPG10163] Expected publication date: TBC
-
Hysteroscopic morcellation of uterine leiomyomas (fibroids)
In development [GID-IPG10165] Expected publication date: TBC
-
Laparoscopic renal denervation
In development [GID-IPG10166] Expected publication date: TBC
-
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]
Proposed [GID-TA10637] Expected publication date: TBC
-
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Proposed [GID-TA10638] Expected publication date: TBC
-
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development [GID-TA10024] Expected publication date: 28 June 2017
-
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)
Proposed [GID-TA10279] Expected publication date: TBC
-
Tocilizumab for treating systemic sclerosis (ID1396)
Proposed [GID-TA10346] Expected publication date: TBC
-
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223
Proposed [GID-HST10019] Expected publication date: TBC
-
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]
In development [GID-TA10046] Expected publication date: 22 November 2017
-
Intravenous zanamivir for treating influenza in hospital [ID1196]
Proposed [GID-TA10298] Expected publication date: TBC
-
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]
In development [GID-TA10636] Expected publication date: TBC
-
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]
Proposed [GID-TA10574] Expected publication date: TBC
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]
In development [GID-TA10611] Expected publication date: TBC
-
Velmanase alfa for treating alpha-mannosidosis [ID800]
In development [GID-HST10010] Expected publication date: TBC
-
Pembrolizumab for previously treated endometrial cancer [ID1205]
In development [GID-TA10243] Expected publication date: TBC
-
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
In development [GID-TA10210] Expected publication date: TBC
-
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
In development [GID-TA10326] Expected publication date: TBC
-
Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]
In development [GID-TA10121] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
In development [GID-TA10405] Expected publication date: TBC
-
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]
In development [GID-TA10473] Expected publication date: TBC
-
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
In development [GID-TA10223] Expected publication date: TBC
-
Cutting blocks for total knee arthroplasty
In development [GID-IP1112] Expected publication date: TBC
-
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
In development [GID-TA10465] Expected publication date: TBC
-
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
In development [GID-TA10486] Expected publication date: TBC
-
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355
In development [GID-TA10321] Expected publication date: TBC
-
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
In development [GID-TA10483] Expected publication date: TBC
-
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
In development [GID-TA10502] Expected publication date: TBC
-
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466
In development [GID-TA10355] Expected publication date: TBC
-
Nintedanib for previously treated metastatic colorectal cancer [ID1030]
In development [GID-TA10138] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]
In development [GID-TA10140] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]
In development [GID-TA10144] Expected publication date: TBC
-
NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)
In development [GID-TA10183] Expected publication date: TBC
-
Nivolumab for treating recurrent glioblastoma [ID998]
In development [GID-TA10126] Expected publication date: TBC
-
Multiple sclerosis (primary-progressive) - fingolimod [ID62]
In development [GID-TAG221] Expected publication date: TBC
-
Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]
In development [GID-TA10688] Expected publication date: TBC
-
NBTXR-3 for treating soft tissue sarcoma [ID1050]
In development [GID-TA10226] Expected publication date: TBC